RFRichard C. Franzese

Richard C. Franzese

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard C. Franzese has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating a Tumor Size‐Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody‐Drug Conjugates in Non‐Small Cell Lung Cancer

    by Mehdi Nikfar, Richard Franzese, Herbert Struemper, Brett Howell, Murad Melhem

    Antibody‐drug conjugate (ADC) development in solid tumors faces efficacy and safety challenges from heterogeneous target expression, limited tumor penetration, and off‐target payload exposure. We developed a spatial quantitative systems pharmacology (QSP) framework integrating ADC‐analyte physiologically based pharmacokinetics (PBPK), a Krogh‐cylinder tumor model, and a non‐small cell lung cancer (NSCLC) tumor size‐overall survival (TS‐OS) relationship developed without ADC‐treated populations. Applied to trastuzumab deruxtecan (T‐DXd) in HER2‐mutant NSCLC and datopotamab deruxtecan (Dato‐DXd), a TROP2‐directed ADC, in EGFR‐mutated NSCLC, all parameters came from literature or independent assays; only nonspecific antibody uptake and unconjugated‐payload hepatic clearances were estimated from population‐level T‐DXd serum PK. Using a common structure and virtual‐patient framework with independently informed ADC‐specific inputs, simulations generated PK, objective response rate (ORR), disease control rate (DCR), and exploratory OS trends consistent with clinical data. Heterogeneous tumor trajectories emerged without fitting individual trajectories, adding ad hoc response compartments, or retuning tumor growth solely to reproduce ORR/DCR. Tumor growth kinetics and target‐expression characteristics, represented by histological score and antigen‐positive cell fraction, were associated with response, but responder/non‐responder distributions overlapped, indicating limited discrimination and need for predictive biomarkers. The TS‐OS sub‐model reproduced median OS and survival trends, supporting transportability despite absent individual‐level tumor and survival data. Tumor growth rate was the strongest survival‐associated input, consistent with TS‐OS covariate structure. Across doses, 5.4 mg/kg Q3W T‐DXd and 6 mg/kg Q3W Dato‐DXd were preferred based on predicted efficacy and off‐tumor tissue payload exposure, consistent with approved doses. The framework supports ADC design and dose evaluation despite limited individual‐level data.

  • Open Access

    Model‐Based Meta‐Analysis of Objective Response Rate and Survival Endpoints to Compare PD ‐1 and PD ‐ L1 Treatment Outcomes in Non‐Small Cell Lung Cancer

    by Richard C. Franzese, Li Qin, Shuai Fu, Benjamin Rich, Eleftherios Zografos, Matthew L. Zierhut, Sandra A. G. Visser

    Programmed cell death (PD) protein (ligand [L])‐1 inhibitors are established treatments for metastatic non‐small cell lung cancer (mNSCLC). In oncology, progression‐free survival (PFS) and objective response rate (ORR) are often used as surrogates for overall survival (OS) to inform clinical development; however, there remains uncertainty in the concordance between these endpoints. This study evaluated the impact of a broad set of PD‐(L)1 inhibitors on efficacy, explored the relationship between ORR and survival endpoints, and compared PD‐1 and PD‐L1 treatments for mNSCLC. A dataset of 114 studies was used to conduct a sequential two‐stage model‐based meta‐analysis (MBMA). Firstly, an MBMA with mixed‐effects logistic regression was applied to evaluate treatment‐specific and clinical covariate effects on ORR. Secondly, MBMAs for OS and PFS were conducted with a mixed‐effects semi‐parametric proportional hazard approach using digitized Kaplan–Meier curves, with the treatment type, covariates, and ORR as inputs. ORR was demonstrated to be a significant predictor of OS and PFS. Simulations of head‐to‐head comparisons of treatment types were conducted using these models. Trends in predicted outcomes numerically favored PD‐1 over PD‐L1 treatments, but differences were not statistically significant. These findings support evidence‐based decision‐making for late‐stage trial designs using ORR data from earlier phase trials, enabling benchmarking of emerging data by adjusting for explained and unexplained sources of variability in existing and emerging data.